Prevention of transfusion-associated graft-versus-host disease with blood product irradiation the past, present, and future

Archives of Pathology and Laboratory Medicine

Volumn 142, Issue 5, 2018, Pages 662-667

  Bahar, Burak ^a   Tormey, Christopher A ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; BLOOD TRANSFUSION REACTION; HUMAN; RADIATION RESPONSE;

BLOOD; HUMANS; TRANSFUSION REACTION;

EID: 85046619967     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2016-0620-RS     Document Type: Review

References (48)

1. Oughterson A, Warren S. Clinical Observations in Hiroshima and Nagasaki. New York, NY: McGraw-Hill; 1956:97–190.
2. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Early effects in man of high dose of radiation. In: Sources, Effects and Risks of Ionizing Radiation. New York, NY: United Nations; 1988:paragraphs 1–89.
3. Vos O, Davids JA, Weyzen WW, Van Bekkum DW. Evidence for the cellular hypothesis in radiation protection by bone marrow cells. Acta Physiol Pharmacol Neerl. 1956;4(4):482–486.
4. van Bekkum D. Graft-versus-host disease. In: van Bekkum DW, Lowenberg B, eds. Bone Marrow Transplantation: Biological Mechanisms and Clinical Practice: New York, NY: Dekker; 1985:162–163.
5. Barnes DWH, Loutit JF, Micklem HS. ‘‘Secondary disease’’ of radiation chimeras: a syndrome due to lymphoid aplasia. Ann N Y Acad Sci. 1962;99(3): 374–385.
6. Shimoda T. Postoperative erythroderma. Geka. 1955;17:487–492.
7. Fliedner VV, Higby DJ, Kim U. Graft-versus-host reaction following blood product transfusion. Am J Med. 1982;72(6):951–961.
8. Thaler M, Shamiss A, Orgad S, et al. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med. 1989;321(1):25–28.
9. Leitman SF, Holland PV. Irradiation of blood products: indications and guidelines. Transfusion. 1985;25(4):293–303.
10. Rolink AG, Gleichmann E. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs.-host (GVH) disease, III: different Lyt subsets of donor T cells induce different pathological syndromes. J Exp Med. 1983;158(2):546–558.
11. Sakakibara T, Juji T. Post-transfusion graft-versus-host disease after open heart surgery. Lancet. 1986;2(8515):1099.
12. Ito K, Yoshida H, Yanagibashi K, et al. Change of HLA phenotype in postoperative erythroderma. Lancet. 1988;1(8582):413–414.
13. Takahashi K, Juji T, Miyazaki H. Post-transfusion graft-versus-host disease occurring in non-immunosuppressed patients in Japan. Transfus Sci. 1991;12(4): 281–289.
14. Petz LD, Calhoun L, Yam P, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion. 1993;33(9):742–750.
15. van Bekkum DW. Transfusion or transplantation? Isr J Med Sci. 1965;1(5): 879–882.
16. Wagner FF, Flegel WA. Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion. 1995;35(4):284–291.
17. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106(6):1901–1910.
18. Panoskaltsis-Mortari A, Price A, Hermanson JR, et al. In vivo imaging of graft-versus-host-disease in mice. Blood. 2004;103(9):3590–3598.
19. Centers for Disease Control and Prevention. National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol. http://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf. Accessed February 27, 2017.
20. Sage D, Stanworth S, Turner D, Navarrete C. Diagnosis of transfusion-associated graft-vs.-host disease: the importance of short tandem repeat analysis. Transfus Med. 2005;15(6):481–485.
21. Rühl H, Bein G, Sachs UJ. Transfusion-associated graft-versus-host disease. Transfus Med Rev. 2009;23(1):62–71.
22. Sprent J, Anderson RE, Miller JF. Radiosensitivity of T and B lymphocytes, II: effect of irradiation on response of T cells to alloantigens. Eur J Immunol. 1974; 4(3):204–210.
23. Button L, DeWolf W, Newburger P, Jacobson M, Kevy S. The effects of irradiation on blood components. Transfusion. 1981;21(4):419–426.
24. Valerius N, Johansen K, Nielsen O, Platz P, Rosenkvist J, Srensen H. Effect of in vitro X-irradiation on lymphocyte and granulocyte function. Scand J Haematol. 1981;27(1):9–18.
25. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease: BCSH Blood Transfusion Task Force. Transfus Med. 1996;6(3):261–271.
26. Fung MK, Grossman BJ, Hillyer C, Westhoff CM. AABB Technical Manual. 18th ed. Bethesda, MD: American Association of Blood Banks; 2014.
27. Goes EG, Borges JC, Covas DT, et al. Quality control of blood irradiation: determination T cells radiosensitivity to cobalt-60 gamma rays. Transfusion. 2006;46(1):34–40.
28. Treleaven J, Gennery A, Marsh J, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol. 2010;152(1):35–51.
29. Asai T, Inaba S, Ohto H, et al. Guidelines for irradiation of blood and blood components to prevent post-transfusion graft-vs.-host disease in Japan. Transfus Med. 2000;10(4):315–320.
30. Singh A, Singh H. Time-scale and nature of radiation-biological damage: approaches to radiation protection and post-irradiation therapy. Prog Biophys Mol Biol. 1982;39(2):69–107.
31. Anand AJ, Dzik WH, Imam A, Sadrzadeh SM. Radiation-induced red cell damage: role of reactive oxygen species. Transfusion. 1997;37(2):160–165.
32. Parkman R, Mosier D, Umansky I, Cochran W, Carpenter CB, Rosen FS. Graft-versus-host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. N Engl J Med. 1974;290(7):359–363.
33. Pritchard AE, Shaz BH. Survey of irradiation practice for the prevention of transfusion-associated graft-versus-host disease. Arch Pathol Lab Med. 2016; 140(10):1092–1097.
34. McCarty JR, Raimer SS, Jarratt M. Toxic epidermal necrolysis from graft-vs-host disease: occurrence in a patient with thymic hypoplasia. Am J Dis Child. 1978;132(3):282–284.
35. US Food and Drug Administration. Circular of Information for the Use of Human Blood And Blood Components. Atlanta, GA: US Food and Drug Administration; 2013:1–72.
36. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the transfusion of red blood cells. Blood Transfus. 2009; 7(1):49–64.
37. Triulzi DJ, Nalesnik MA. Microchimerism, GVHD, and tolerance in solid organ transplantation. Transfusion. 2001;41(3):419–426.
38. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med. 1978;299(15):799–803.
39. Kopolovic I, Ostro J, Tsubota H, et al. A systematic review of transfusion-associated graft-versus-host disease. Blood. 2015;126(3):406–414.
40. US Food and Drug Administration. Fatalities reported to the Food and Drug Administration following blood collection and transfusion. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ default.htm. Accessed February 27, 2017.
41. Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutierrez L. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci. 2015; 52(1):19–34.
42. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol. 2001;38(4)(suppl 11):4–11.
43. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant. 2004; 33(1):1–7.
44. US Food and Drug Administration. INTERCEPT blood system for platelets. https://www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/premarketapprovalspmas/ucm427488.htm. Accessed February 27, 2017.
45. Fast LD, Nevola M, Tavares J, Reddy HL, Goodrich RP, Marschner S. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion. 2013;53(2):373–381.
46. Mintz PD, Wehrli G. Irradiation eradication and pathogen reduction: ceasing cesium irradiation of blood products. Bone Marrow Transplant. 2009; 44(4):205–211.
47. Wiltshire M, Meli A, Schott MA, et al. Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation. Transfus Med. 2016;26(3):208–214.
48. Janatpour K, Denning L, Nelson K, Betlach B, Mackenzie M, Holland P. Comparison of X-ray vs. gamma irradiation of CPDA-1 red cells. Vox Sang. 2005; 89(4):215–219.